Pharmacogenomics addresses the challenge of inter-individual variability in drug effectiveness and toxicity by studying molecular factors that affect drug pharmacokinetics and pharmacodynamics. These studies aim to improve our understanding of mechanisms underlying differences in drug response between patients and identify predictive markers to identify patients with an increased risk of suboptimal therapeutic outcomes. As a result, pharmacogenomics can offer additional guidance for clinical decision-making related to drug therapies in order to further tailor treatments towards the individual needs of each patient. Pharmacogenomics is thus an essential component of personalized medicine and precision medicine. Moreover, pharmacogenomics is a multidisciplinary science that brings together clinicians and scientists in various fields such as pharmacology, genetics, molecular biology, and laboratory medicine. To deliver on the great potential of pharmacogenomics and translate research findings into tangible benefits for patients, inter-disciplinary collaboration is thus a key feature of this discipline.
To foster such collaboration and offer a platform for the exchange of information and ideas over a broad spectrum of scientific disciplines, the Swiss Group of Pharmacogenomics and Personalized Therapy (SPT) was created in February of 2016 as a section within the Swiss Society of Clinical Pharmacology and Toxicology (SSCPT). To coordinate efforts also internationally, SPT serves as a national organization linked to the European Society of Pharmacogenomics and Personalized Therapy (ESPT).
The goals of SPT are to promote a vision of pharmacogenomics and personalised medicine in Switzerland; to provide education to improve clinicians’ and patients’ understanding and use of pharmacogenomics; to inform and offer an independent view of pharmacogenomics and personalized medicine to regulators, the public and other stakeholders; and to promote scientific research in this field.